Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Phreesia (NYSE:PHR) in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 2 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 2 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $29.83, a high estimate of $34.00, and a low estimate of $28.00. A decline of 4.79% from the prior average price target is evident in the current average.
Decoding Analyst Ratings: A Detailed Look
In examining recent analyst actions, we gain insights into how financial experts perceive Phreesia. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jailendra Singh | Truist Securities | Maintains | Buy | $29.00 | $29.00 |
| Jailendra Singh | Truist Securities | Lowers | Buy | $29.00 | $35.00 |
| Richard Close | Canaccord Genuity | Lowers | Buy | $34.00 | $37.00 |
| Jeff Garro | Stephens & Co. | Maintains | Overweight | $28.00 | $28.00 |
| Joe Goodwin | JMP Securities | Maintains | Market Outperform | $30.00 | $30.00 |
| Ryan MacDonald | Needham | Maintains | Buy | $29.00 | $29.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Phreesia. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Phreesia compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Phreesia's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Capture valuable insights into Phreesia's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Phreesia analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
All You Need to Know About Phreesia
Phreesia Inc is a provider of comprehensive software solutions that improves the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, but not limited to, initial patient contact, registration, appointment scheduling, payments, and post-appointment patient surveys.
Understanding the Numbers: Phreesia's Finances
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Phreesia displayed positive results in 3 months. As of 30 April, 2024, the company achieved a solid revenue growth rate of approximately 20.72%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -19.48%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Phreesia's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -7.82%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Phreesia's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -5.31%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Phreesia's debt-to-equity ratio is below the industry average. With a ratio of 0.07, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyst Ratings: Simplified
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.